Home › Medulloblastoma
Medulloblastoma clinical trials recruiting in the U.S.
24 studies for Medulloblastoma are recruiting participants at sites across the United States.
Cities with the most studies
- Washington, DC9 studies
- St. Louis, MO6 studies
- Miami, FL4 studies
- Durham, NC4 studies
- Philadelphia, PA4 studies
- Tampa, FL4 studies
- New York City, NY4 studies
- Seattle, WA4 studies
- Houston, TX4 studies
- Chicago, IL3 studies
- Minneapolis, MN3 studies
- Ann Arbor, MI3 studies
- Little Rock, AR3 studies
- Cincinnati, OH3 studies
- San Diego, CA3 studies
- Columbus, OH3 studies
- Hartford, CT3 studies
- Dallas, TX3 studies
- San Francisco, CA3 studies
- St. Petersburg, FL3 studies
- Austin, TX3 studies
- Orlando, FL3 studies
- Charlotte, NC3 studies
- Boston, MA3 studies
- Memphis, TN3 studies
- Mountain View, CA3 studies
By state
- Alabama3 studies
- Arkansas3 studies
- California6 studies
- Connecticut3 studies
- District of Columbia7 studies
- Florida6 studies
- Georgia3 studies
- Illinois3 studies
- Kentucky3 studies
- Maryland4 studies
- Massachusetts3 studies
- Michigan4 studies
- Minnesota3 studies
- Missouri6 studies
- New Jersey3 studies
- New York5 studies
- North Carolina4 studies
- Ohio3 studies
- Pennsylvania5 studies
- Tennessee5 studies
- Texas8 studies
- Washington4 studies
Recently updated studies
Liothyronine in Combination With BIT Regimen for Medulloblastoma With or Without Minimal Residual Disease
RecruitingPhase 1/2
Ages 1 to 25 · All sexes · Updated Sep 28, 2026 · NCT07346157Cognitive Rehabilitation for Survivors of Childhood Medulloblastoma Using Real Time Hemodynamic Neurofeedback
Recruiting
Ages 10 to 25 · All sexes · Updated Sep 23, 2026 · NCT07830134Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma
RecruitingPhase 2
59 Months · All sexes · Updated Sep 15, 2026 · NCT05535166GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young Adults
RecruitingPhase 1
Ages 1 to 30 · All sexes · Updated Sep 11, 2026 · NCT07087002Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors
RecruitingPhase 2
Up to age 19 · All sexes · Updated Sep 10, 2026 · NCT01356290HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
RecruitingPhase 1
36 Months – 22 Years · All sexes · Updated Sep 4, 2026 · NCT03911388B7-H3.CD28Z.CART in CNS Neoplasms
RecruitingPhase 1
Ages 2 to 21 · All sexes · Updated Sep 3, 2026 · NCT07390539Relapsed and Progressive Sonic Hedgehog Medulloblastoma With U1 Mutation Registry Study
RecruitingObservational study
Ages 3 to 50 · All sexes · Updated Sep 1, 2026 · NCT07242963Digoxin Medulloblastoma Study
RecruitingPhase 2
12 Months – 30 Years · All sexes · Updated Aug 26, 2026 · NCT06701812A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss
RecruitingPhase 3
Ages 4 to 21 · All sexes · Updated Aug 25, 2026 · NCT05382338PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma
RecruitingPhase 2
Ages 3 to 39 · All sexes · Updated Aug 24, 2026 · NCT05096481DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma
RecruitingPhase 2
Up to age 21 · All sexes · Updated Aug 12, 2026 · NCT04696029PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications
RecruitingPhase 1/2
Ages 18 to 120 · All sexes · Updated Aug 12, 2026 · NCT06161519Individualized Treatment Plan in Children and Young Adults With Relapsed Medulloblastoma and Ependymoma
Recruiting
12 Months – 39 Years · All sexes · Updated Aug 11, 2026 · NCT05057702Adoptive T Cell Therapy, DC Vaccines, and Hematopoietic Stem Cells Combined With Immune checkPOINT Blockade in Patients With Medulloblastoma
RecruitingPhase 1
Ages 4 to 30 · All sexes · Updated Aug 7, 2026 · NCT06514898Atovaquone Combined With Radiation in Children With Malignant Brain Tumors
RecruitingPhase 1
Ages 2 to 25 · All sexes · Updated Aug 3, 2026 · NCT06624371Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
RecruitingPhase 1/2
Ages 4 to 39 · All sexes · Updated Jul 20, 2026 · NCT05278208A Study of 177Lu-DTPA-Omburtamab in Children and Adolescents With Brain Cancer or Cancer That Has Spread to the Central Nervous System (CNS)
RecruitingPhase 1
Ages 3 to 22 · All sexes · Updated Jul 13, 2026 · NCT07698899CSIMEMPHIS: Long-term Follow-up of Medulloblastoma Survivors That Received Craniospinal Irradiation
RecruitingObservational study
All ages · All sexes · Updated Jul 6, 2026 · NCT07085325Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT)
RecruitingPhase 1
Ages 1 to 30 · All sexes · Updated Jun 17, 2026 · NCT06193759Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors
RecruitingPhase 1
Ages 1 to 26 · All sexes · Updated Apr 13, 2026 · NCT04185038Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer
RecruitingPhase 1
Ages 3 to 25 · All sexes · Updated Jan 9, 2026 · NCT05106296Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Dec 18, 2025 · NCT0454108268-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors.
RecruitingPhase 4
Ages 18 to 100 · All sexes · Updated Nov 21, 2025 · NCT04081701From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.